DOP2017000136A - Compuestos para tratar el cáncer - Google Patents

Compuestos para tratar el cáncer

Info

Publication number
DOP2017000136A
DOP2017000136A DO2017000136A DO2017000136A DOP2017000136A DO P2017000136 A DOP2017000136 A DO P2017000136A DO 2017000136 A DO2017000136 A DO 2017000136A DO 2017000136 A DO2017000136 A DO 2017000136A DO P2017000136 A DOP2017000136 A DO P2017000136A
Authority
DO
Dominican Republic
Prior art keywords
compounds
treat cancer
mps
prophylaxis
diseases
Prior art date
Application number
DO2017000136A
Other languages
English (en)
Inventor
Schulze Volker
Siemeister Gerhard
Lienau Philip
Lerchen Hans-Georg
Krenz Ursula
Margret Wengner Antje
Lücking Ulrich
Original Assignee
Bayer Pharma Aktiegellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma Aktiegellschaft filed Critical Bayer Pharma Aktiegellschaft
Publication of DOP2017000136A publication Critical patent/DOP2017000136A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

Derivados de profármacos de inhibidores de la quinasa Mps-1 y su uso en el tratamiento y/o la profilaxis de enfermedades.
DO2017000136A 2014-12-09 2017-06-09 Compuestos para tratar el cáncer DOP2017000136A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14196859 2014-12-09

Publications (1)

Publication Number Publication Date
DOP2017000136A true DOP2017000136A (es) 2017-08-31

Family

ID=52011093

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2017000136A DOP2017000136A (es) 2014-12-09 2017-06-09 Compuestos para tratar el cáncer

Country Status (27)

Country Link
US (1) US20170342064A1 (es)
EP (1) EP3230285A1 (es)
JP (1) JP2017537116A (es)
KR (1) KR20170088872A (es)
CN (1) CN107001376A (es)
AR (1) AR102947A1 (es)
AU (1) AU2015359593A1 (es)
BR (1) BR112017012317A2 (es)
CA (1) CA2969902A1 (es)
CO (1) CO2017005741A2 (es)
CR (1) CR20170243A (es)
CU (1) CU20170078A7 (es)
DO (1) DOP2017000136A (es)
EA (1) EA201791264A1 (es)
EC (1) ECSP17036251A (es)
IL (1) IL252237A0 (es)
MA (1) MA41136A (es)
MX (1) MX2017007655A (es)
NI (1) NI201700072A (es)
PE (1) PE20170927A1 (es)
PH (1) PH12017501063A1 (es)
SG (1) SG11201704684PA (es)
TN (1) TN2017000241A1 (es)
TW (1) TW201625565A (es)
UY (1) UY36421A (es)
WO (1) WO2016091825A1 (es)
ZA (1) ZA201704589B (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101395158A (zh) * 2006-03-07 2009-03-25 百时美施贵宝公司 可作为激酶抑制剂的吡咯并三嗪苯胺前体药物化合物
UA112096C2 (uk) * 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
RS56034B1 (sr) * 2013-06-11 2017-09-29 Bayer Pharma AG Derivati prolekova supstituisanih triazolopiridina

Also Published As

Publication number Publication date
KR20170088872A (ko) 2017-08-02
CR20170243A (es) 2017-07-26
ECSP17036251A (es) 2017-06-30
CA2969902A1 (en) 2016-06-16
BR112017012317A2 (pt) 2018-04-24
AU2015359593A1 (en) 2017-06-08
UY36421A (es) 2016-06-30
SG11201704684PA (en) 2017-07-28
MX2017007655A (es) 2017-10-11
AR102947A1 (es) 2017-04-05
JP2017537116A (ja) 2017-12-14
US20170342064A1 (en) 2017-11-30
ZA201704589B (en) 2019-02-27
TN2017000241A1 (en) 2018-10-19
EA201791264A1 (ru) 2017-12-29
WO2016091825A1 (en) 2016-06-16
NI201700072A (es) 2017-07-17
TW201625565A (zh) 2016-07-16
CN107001376A (zh) 2017-08-01
MA41136A (fr) 2017-10-17
PE20170927A1 (es) 2017-07-13
PH12017501063A1 (en) 2017-12-11
CO2017005741A2 (es) 2017-08-31
CU20170078A7 (es) 2017-10-05
IL252237A0 (en) 2017-07-31
EP3230285A1 (en) 2017-10-18

Similar Documents

Publication Publication Date Title
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
MX2020003702A (es) Ciclopropilaminas como inhibidores de desmetilasa especifica de lisina 1 (lsd1).
BR112018010464A2 (pt) formulações farmacêuticas tópicas para tratar condições inflamatórias relacionadas
PE20180243A1 (es) Composiciones que comprenden cepas bacterianas
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
MX2017006302A (es) Derivados de adenina que son utiles en el tratamiento de enfermedades alergicas u otras afecciones inflamatorias.
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
TW201613860A (en) Cyclopropylamines as LSD1 inhibitors
BR112017011771A2 (pt) métodos e composições para o tratamento de câncer
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
BR112018000776A2 (pt) métodos para tratamento de câncer usando apilimod
MX2019013808A (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer.
BR112017009000A2 (pt) apilimod para uso no tratamento de melanoma
PH12016501838A1 (en) Compounds and their methods of use
UY36286A (es) Tratamientos médicos basados en anamorelina
CR20150659A (es) Derivados de prodroga de triazolpiridinas sustituidas
ES2759940T8 (es) Compuestos de 1,3,4-tiadiazol y su uso para tratar el cáncer
DOP2017000136A (es) Compuestos para tratar el cáncer
GB2546703A (en) Compounds